Haemonetics Corp. (HAE) Tops Q3 EPS by 6c; Affirms FY12 EPS Outlook
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $81.24 -2.66%
EPS Growth %: +15.6%
Financial Fact:
Gross profit: 104.25M
Today's EPS Names:
MAXN, CSTR, ACU, More
EPS Growth %: +15.6%
Financial Fact:
Gross profit: 104.25M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q3 EPS of $0.86, $0.06 better than the analyst estimate of $0.80. Revenue for the quarter came in at $191.2 million versus the consensus estimate of $186.21 million.
Affirms outlook.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Affirms outlook.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Growth isn't weak enough to truly undercut inflation pressures - BMO
- MetroCity Bankshares, Inc. (MCBS) Tops Q1 EPS by 4c
- Park National Corp. (PRK) Tops Q1 EPS by 36c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
